Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scFv-CH3) contains two chains. The anti-doxorubicin scFv is fused to the Knob-CH3 domain via a hinge region and the same as the anti-EGFR scFv to the Hole-CH3 domain, or vice versa. The KIH CH3 domains can facilitate to form a heterodimer and this bivalent binding leads to improvement in avidity. This BsAb can be used in pretargeting system and deliver toxin to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scFv-CH3) (BSFC-151). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS